ATE533859T1 - MARKER FÜR NIERENTRANSPLANTATABSTOßUNG UND NIERENSCHÄDEN - Google Patents

MARKER FÜR NIERENTRANSPLANTATABSTOßUNG UND NIERENSCHÄDEN

Info

Publication number
ATE533859T1
ATE533859T1 AT07253514T AT07253514T ATE533859T1 AT E533859 T1 ATE533859 T1 AT E533859T1 AT 07253514 T AT07253514 T AT 07253514T AT 07253514 T AT07253514 T AT 07253514T AT E533859 T1 ATE533859 T1 AT E533859T1
Authority
AT
Austria
Prior art keywords
kidney
markers
transplant rejection
damage
renal
Prior art date
Application number
AT07253514T
Other languages
English (en)
Inventor
Stefan Kienle
Richard Joubert
Original Assignee
Electrophoretics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Electrophoretics Ltd filed Critical Electrophoretics Ltd
Application granted granted Critical
Publication of ATE533859T1 publication Critical patent/ATE533859T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT07253514T 2006-09-05 2007-09-05 MARKER FÜR NIERENTRANSPLANTATABSTOßUNG UND NIERENSCHÄDEN ATE533859T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0617429.6A GB0617429D0 (en) 2006-09-05 2006-09-05 Markers of renal transplant rejection and renal damage

Publications (1)

Publication Number Publication Date
ATE533859T1 true ATE533859T1 (de) 2011-12-15

Family

ID=37232368

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07253514T ATE533859T1 (de) 2006-09-05 2007-09-05 MARKER FÜR NIERENTRANSPLANTATABSTOßUNG UND NIERENSCHÄDEN

Country Status (6)

Country Link
US (2) US8021895B2 (de)
EP (2) EP2333116B1 (de)
AT (1) ATE533859T1 (de)
CA (1) CA2600168A1 (de)
ES (1) ES2379430T3 (de)
GB (1) GB0617429D0 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2153234A2 (de) * 2007-05-11 2010-02-17 The Institutes for Pharmaceutical Discovery, LLC Verfahren zur frühdiagnose einer nierenerkrankung
AU2009235924A1 (en) * 2008-04-10 2009-10-15 The University Of British Columbia Methods of diagnosing chronic cardiac allograft rejection
AU2009253696A1 (en) * 2008-05-30 2009-12-03 The University Of British Columbia Methods of diagnosing rejection of a kidney allograft using genomic or proteomic expression profiling
US11150250B2 (en) * 2008-08-28 2021-10-19 Astute Medical, Inc. Methods for diagnosing acute kidney injury or renal failure
EP2324354B1 (de) 2008-08-29 2014-07-16 Astute Medical, Inc. Verfahren zur prognose von akuter niereninsuffizienz
EP3974836A1 (de) 2008-10-21 2022-03-30 Astute Medical, Inc. Verfahren und zusammensetzungen zur diagnose und prognose von nierenläsion und niereninsuffizienz
JP2012506538A (ja) * 2008-10-21 2012-03-15 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後のための方法および組成物
CN104330574B (zh) 2008-11-10 2017-04-12 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
CN103439510B (zh) * 2008-11-22 2016-09-14 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN104111336B (zh) * 2009-02-06 2017-01-18 阿斯图特医药公司 肾损伤和肾衰竭的诊断及预后
US20110065136A1 (en) * 2009-08-07 2011-03-17 Rules-Based Medicine, Inc. Methods and Devices for Detecting Glomerulonephritis and Associated Disorders
CA2770393A1 (en) * 2009-08-07 2011-02-10 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20130045494A1 (en) * 2009-09-18 2013-02-21 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2480882A4 (de) * 2009-09-21 2013-07-10 Astute Medical Inc Verfahren und zusammensetzungen zur diagnose und prognose von nierenverletzungen und niereninsuffizienz
EP2488661B1 (de) * 2009-10-14 2014-12-24 Oberbauer, Rainer Prüfung auf Risiko einer akuten Nierenverletzung
WO2011057147A1 (en) 2009-11-07 2011-05-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US10830773B2 (en) * 2009-12-20 2020-11-10 Astute Medical, Inc. Methods for prognosis of future acute renal injury and acute renal failure
HUE029304T2 (en) 2010-02-05 2017-02-28 Astute Medical Inc Procedures and Preparations for Diagnosing and Predicting Kidney Damage and Kidney Failure
NZ602056A (en) 2010-02-26 2014-11-28 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ605698A (en) 2010-06-23 2015-03-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
IN2012MN02812A (de) 2010-06-23 2015-05-22 Astute Medical Inc
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
ES2933570T3 (es) 2011-12-08 2023-02-10 Astute Medical Inc Métodos y composiciones para el diagnóstico y el pronóstico de una lesión renal y de una insuficiencia renal
JP2015524926A (ja) * 2012-08-03 2015-08-27 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
AU2014207509B2 (en) 2013-01-17 2019-12-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US10300108B2 (en) 2013-12-03 2019-05-28 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2944990A1 (en) 2014-04-09 2015-10-15 The Regents Of The University Of California Protein biomarkers for immune assessment and prediction of transplant rejection
US9764078B2 (en) * 2014-06-06 2017-09-19 The University Of Manchester Extracorporeal removal of anti-IQCJ antibodies from blood
US11243202B2 (en) 2015-04-09 2022-02-08 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2016178121A1 (en) 2015-05-01 2016-11-10 The University Of British Columbia Biomarkers for the detection of acute rejection in heart transplantation
AU2017277305A1 (en) 2016-06-06 2018-12-20 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
CN113092769A (zh) * 2019-12-23 2021-07-09 首都医科大学附属北京世纪坛医院 尿液补体c4-a及其多肽片段在过敏性疾病中的应用
KR102314642B1 (ko) * 2020-04-17 2021-10-20 재단법인 아산사회복지재단 파브리 병 진단용 바이오 마커 및 이의 용도
EP4397976A1 (de) * 2023-01-09 2024-07-10 x-kidney diagnostics GmbH Biomarker zur präklinischen und/oder frühen erkennung und/oder diagnose von nierenerkrankungen
WO2025183579A1 (en) 2024-02-29 2025-09-04 Ramalhete Lus Manuel Pires Prognostic method for determining a probability of allograft rejection

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4731326A (en) * 1984-06-04 1988-03-15 Ortho Diagnostic Systems Inc. Disease diagnosis by detection of shed normal tissue antigens
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5591721A (en) 1994-10-25 1997-01-07 Hybridon, Inc. Method of down-regulating gene expression
WO1996037777A1 (en) * 1995-05-23 1996-11-28 Nelson Randall W Mass spectrometric immunoassay
AU9510498A (en) * 1997-09-26 1999-04-12 University Of Washington Methods and compositions for diagnosing renal pathologies
US6406921B1 (en) * 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
DE60032784T2 (de) 1999-10-07 2007-11-08 Ciphergen Biosystems, Inc., Fremont Markerproteine für prostatakrebs
US20030003588A1 (en) * 2001-06-28 2003-01-02 Comper Wayne D. Method for kidney disease detection by protein profiling
AU2002328630B2 (en) * 2001-08-17 2005-09-01 Fujirebio Inc. Method of diagnosing or monitoring saccharometabolic error
NZ543028A (en) * 2003-03-27 2008-06-30 Childrens Hosp Medical Center A method for detecting the early onset of renal tubular cell injury

Also Published As

Publication number Publication date
US8021895B2 (en) 2011-09-20
EP2333116A2 (de) 2011-06-15
EP2333116B1 (de) 2015-05-06
EP2333116A3 (de) 2011-10-12
EP1905846B1 (de) 2011-11-16
GB0617429D0 (en) 2006-10-18
US20080153092A1 (en) 2008-06-26
US8741580B2 (en) 2014-06-03
EP1905846A3 (de) 2008-07-09
US20120065095A1 (en) 2012-03-15
CA2600168A1 (en) 2008-03-05
EP1905846A2 (de) 2008-04-02
ES2379430T3 (es) 2012-04-26

Similar Documents

Publication Publication Date Title
ATE533859T1 (de) MARKER FÜR NIERENTRANSPLANTATABSTOßUNG UND NIERENSCHÄDEN
EP1848739A4 (de) Adamts-7 als biomarker für epithelkrebs
DE602007003165D1 (de) Verfahren und Systeme zur Definition, Identifikation und Erfassung geometrischer Eigenschaften
EP1997271A4 (de) Einzel-sign-on zwischen systemen
IL189263B (en) Identification and engineering of antibodies with variant fc regions and methods of using same
DE602007011545D1 (de) Automatisches System zur Durchführung von lokalisierten Bestandsaufnahmen
DK1974210T3 (da) Fremgangsmåde til diagnosticering af polycystisk nyresygdom
DE602006017335D1 (de) Sensoranordnung für sattelkupplung
ATE499453T1 (de) Zugerichtetes leder
EP2358907A4 (de) Mit autismus assoziierte genetische marker
DK2024747T3 (da) Anvendelse af protein SATB2 som prognotisk markør for colerectal cancer
DK2021792T3 (da) Opløste protein-artritmarkører
BRPI0714209A2 (pt) Induzidor de morte celular
ATE479699T1 (de) Neue markierungsstrategien für den empfindlichen nachweis von analyten
BR112012013418A2 (pt) marcador sérico bioquímico.
DE602006011229D1 (de) System zur Stromsymmetrierung
FI20055198A0 (fi) Visualisointitekniikka biologista infomaatiota varten
DE602006013109D1 (de) Markerprotein zur verwendung bei der diagnose von bauchspeicheldrüsenkrebs
ITBO20060366A1 (it) Centro di lavoro per la lavorazione di pezzi in legno od assimilabili.
DE502004006249D1 (de) Informationssystem für Fortbewegungsmittel
DE602006000859D1 (de) Werkzeug zur Bearbeitung von Rohren
DE602006005624D1 (de) Metaboliten für nk-i-antagonisten zur emesis
DE602005014025D1 (de) Nachweisreagenz für Noroviridae
DE602006018146D1 (de) Markierungsring für Brieftauben
EP4038205C0 (de) Klinische und molekulare prognosemarker für lebertransplantation